Diabetes mellitus, un reto diagnóstico
DOI:
https://doi.org/10.32818/reccmi.a3s1a4Keywords:
LADA, type 1 diabetes mellitus, type 2 diabetes mellitus, Addison diseaseAbstract
Diabetes mellitus (DM) comprises a group of metabolic diseases that have the presence of hyperglycemia as a common factor. In Spain, the prevalence estimates of DM type 2 (DM2) ranging between 4.8 and 18.7%, DM type 1 (DM1) between 0.08 and 0.2%; are a major health problem due to the associated comorbidity and high costs. The aim of the case study is to raise awareness of the importance of early and adequate diagnosis among health professionals in order to optimize treatment; in addition to proposing a differential diagnosis of importance for routine clinical practice.
Downloads
Metrics
References
Tuomi T, Groop LC, Zimmet PZ, et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non insulin-dependent onset of disease. Diabetes. 1993; 42: 359.
Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA. 2007; 104: 17040.
Pettersen E, Skorpen F, Kvaløy K, et al. Genetic heterogeneity in latent autoimmune diabetes is linked to various degrees of autoimmune activity: results from the Nord-Trøndelag Health Study. Diabetes. 2010; 59: 302.
Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985; 34: 222.
Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985; 6: 45.
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Diego Eduardo Olivo-Aguilar, Carlos Tarrazo-Tarrazo, José Javier Garrido-Sánchez, Jaime Casal-Álvarez, Víctor Arenas-García
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
